94 related articles for article (PubMed ID: 2749609)
1. Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists?
Petty AC; Scrutton MC
Thromb Res; 1989 Apr; 54(2):151-9. PubMed ID: 2749609
[No Abstract] [Full Text] [Related]
2. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.
Adamus WS; Heuer H; Meade CJ
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):415-20. PubMed ID: 2747341
[TBL] [Abstract][Full Text] [Related]
3. Platelet activating factor and sheep platelets: a sensitive new bioassay.
Moon DG; van der Zee H; Morton KD; Krasodomski JA; Kaplan JE; Fenton JW
Thromb Res; 1990 Feb; 57(4):551-64. PubMed ID: 2326773
[TBL] [Abstract][Full Text] [Related]
4. Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guinea-pig and platelet aggregation in man.
Evans TW; Dent G; Rogers DF; Aursudkij B; Chung KF; Barnes PJ
Br J Pharmacol; 1988 May; 94(1):164-8. PubMed ID: 3401633
[TBL] [Abstract][Full Text] [Related]
5. The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF).
Griffin KJ; Levy JV
Thromb Res; 1988 Jul; 51(2):219-23. PubMed ID: 3187959
[No Abstract] [Full Text] [Related]
6. Calcium-dependent synergistic interaction of platelet activating factor and epinephrine in human platelet aggregation.
Saeed SA; Rasheed H
Acta Pharmacol Sin; 2003 Jan; 24(1):31-6. PubMed ID: 12511226
[TBL] [Abstract][Full Text] [Related]
7. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
8. Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation.
Fouque F; Vargaftig BB
Br J Pharmacol; 1984 Nov; 83(3):625-33. PubMed ID: 6439269
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
[TBL] [Abstract][Full Text] [Related]
10. Platelet-activating factor (Paf) antagonist, WEB 2086, protects against Paf-induced hypotension in Macaca fascicularis.
Stanton AW; Izumi T; Antoniw JW; Piper PJ
Br J Pharmacol; 1989 Jul; 97(3):643-6. PubMed ID: 2758235
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms involved in human platelet aggregation by synergistic interaction of platelet-activating factor and 5-hydroxytryptamine.
Shah BH; Rasheed H; Rahman IH; Shariff AH; Khan FL; Rahman HB; Hanif S; Saeed SA
Exp Mol Med; 2001 Dec; 33(4):226-33. PubMed ID: 11795484
[TBL] [Abstract][Full Text] [Related]
12. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
Griffin K; Hong T; Levy JV
Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748
[TBL] [Abstract][Full Text] [Related]
13. The effect of Paf antagonists on bronchial hyperresponsiveness induced by Paf, propranolol or indomethacin.
Dixon EJ; Wilsoncroft P; Robertson DN; Page CP
Br J Pharmacol; 1989 Jul; 97(3):717-22. PubMed ID: 2758238
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition by two hetrazepine PAF antagonists of acute inflammation in the mouse.
Henriques MG; Weg VB; Martins MA; Silva PM; Fernandes PD; Cordeiro RS; Vargaftig BB
Br J Pharmacol; 1990 Jan; 99(1):164-8. PubMed ID: 2331569
[TBL] [Abstract][Full Text] [Related]
16. A possible role for PAF in allergen-induced late responses: modification by a selective antagonist.
Abraham WM; Stevenson JS; Garrido R
J Appl Physiol (1985); 1989 May; 66(5):2351-7. PubMed ID: 2745300
[TBL] [Abstract][Full Text] [Related]
17. Induction of platelet aggregation in vitro by microbubbles of nitrogen.
Thorsen T; Lie RT; Holmsen H
Undersea Biomed Res; 1989 Nov; 16(6):453-64. PubMed ID: 2603242
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
19. Collagen induced human platelet aggregation: serotonin receptor antagonism retards aggregate growth in vitro.
Menys VC
Cardiovasc Res; 1993 Nov; 27(11):1916-9. PubMed ID: 8287397
[TBL] [Abstract][Full Text] [Related]
20. Effect of a new and specific PAF-antagonist, WEB 2086, on PAF and endotoxin/tumor necrosis factor induced changes in mortality and intestinal transit velocity.
Heuer H
Prog Clin Biol Res; 1989; 308():919-24. PubMed ID: 2780739
[No Abstract] [Full Text] [Related]
[Next] [New Search]
